Toujeo Logo

InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo and insulin degludec 100U/mL in people with T1DM

InRange Clinical Summary

Download this six page clinical summary about the InRange study and learn more about the study design, the key findings and more. 

InRange Study

In this 22 minute video Professor Richard Bergenstal presents the results of the InRange study, the first randomised controlled trial to compare second generation basal insulin analogues Toujeo and insulin degludec 100 U/mL, in adults with T1DM, using Time-in-Range (TIR) as the primary endpoint. You will learn more about the study design and the key findings from this study.
 

Time-in-Range Study Design

Watch this 2.30 min video on the InRange* study design. Alternatively, you can also download the published paper below.

*The InRange study has been sponsored by Sanofi

Time in Range Guide

To find out more about Time-In-Range and the impact it can have on your patients, download the guide below.

Woman on the telephone

Always up to date?

Webinars, evidence, expert videos, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.

MAT-IE-2001763 (v6.0)
Date of preparation: January 2024